Accessibility Menu
Merck KGaA logo

Merck KGaA(OTC) MKGAF

Market Cap$73.43BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)+513%
5 Year-13%
1 Year+36%
1 Month+2%
$168.90
-0.13%
-0.22Today
Merck KGaA last closing stock price
MetricPriceDate
Last closeUSD 168.902026-07-31
Merck KGaA stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.62%USD 159.922026-07-24
1 month+1.8%USD 165.912026-07-01
3 month+28.78%USD 131.152026-05-01
Year to date+16.73%USD 144.692025-12-31
1 year+35.51%USD 124.642025-07-31
3 year+3.26%USD 163.572023-08-01
5 year-13.46%USD 195.182021-07-30
Since inception+512.94%USD 27.562003-06-25

Merck KGaA Financials at a Glance

Market Cap

$73.43BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€20.97B

Net Income (TTM)

€2.54B

EPS (TTM)

$6.75

P/E Ratio

25.02

Dividend

$2.58

Beta (Volatility)

0.48 (Low)

Price

$168.90

Volume

467

Open

$171.39

Previous Close

$168.90

Daily Range

$160.55 - $172.23

52-Week Range

$116.68 - $175.56

Estimated Earnings Date

Aug 6, 2026

MKGAF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Merck KGaA

Merck KGaA is a leading science and technology company based in Darmstadt, Germany, with a rich history dating back to 1668. The company operates through three main divisions: Life Science, Healthcare, and Electronics, providing innovative solutions across various sectors.

Products and Services
  • Life Science division offers specialized chemicals and advanced equipment for research and biotechnology
  • Healthcare segment focuses on prescription medications and biopharmaceuticals for various medical conditions
  • Electronics division supplies essential materials for semiconductor and display manufacturing
Growth Outlook
  • Recent partnerships enhance the therapeutic pipeline, targeting critical oncogenic proteins
  • Continued investment in R&D supports innovation in drug development and manufacturing processes
  • Expansion in emerging markets is expected to drive revenue growth in the coming years
Financial Highlights
  • Q1 2026 revenue of €5.15 billion reflects strong demand across all divisions
  • Net income for Q1 2026 reached €662 million, showcasing robust profitability
  • Trailing twelve months (TTM) net profit margin stands at 12.09%, indicating efficient operations
Merck KGaA's diverse portfolio and strategic partnerships position the company well for future growth. The Life Science division continues to innovate, providing essential tools and services to the biotechnology and pharmaceutical industries. The Healthcare segment's focus on developing treatments for complex diseases enhances its market presence. Additionally, the Electronics division plays a crucial role in the semiconductor industry, which is poised for growth. Recent financial performance indicates a solid foundation, with significant revenue and net income figures, reflecting the company's operational efficiency and market demand. Overall, Merck KGaA presents a compelling opportunity for investors interested in a well-established company with a strong growth trajectory.
AI Generated • Jul 20, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

62,477

CEO

Belén Garijo López, MD

Website

www.merckgroup.com

Headquarters

Darmstadt, HE 64293, DE

MKGAF Financials

Key Financial Metrics (TTM)

Gross Margin

58.53%

Operating Margin

19.41%

Net Income Margin

12.09%

Return on Equity

8.77%

Return on Capital

10.02%

Return on Assets

4.77%

Earnings Yield

4.00%

Dividend Yield

1.53%

Payout Ratio

11.76%

Stock Overview

Market Cap

$73.43BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

434.78M

Volume

467

Avg. Volume

692.889

Financials (TTM)

Gross Profit

€12.28B

Operating Income

€3.89B

EBITDA

€6.55B

Operating Cash Flow

€4.46B

Capital Expenditure

-€1.76B

Free Cash Flow

€2.70B

Cash & ST Invst.

€3.77B

Total Debt

€12.08B

Merck KGaA Performance Analysis

Merck KGaA annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 23,365,261,0070.4%
20232023-12-31EUR 22,695,859,854-2.9%
20242024-12-31EUR 22,884,249,6410.8%
20252025-12-31EUR 23,815,251,9134.1%
Merck KGaA sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-0.5%
Q32025-09-301.2%
Q42025-12-31-1.3%
Q12026-03-31-1.8%
Merck KGaA annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 8.04-3.2%
20232023-12-31EUR 7.02-12.7%
20242024-12-31EUR 6.91-1.6%
20252025-12-31EUR 6.77-2.0%
Merck KGaA sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-11.2%
Q32025-09-3038.0%
Q42025-12-31-64.7%
Q12026-03-31108.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

€5.15B

-2.4%

Gross Profit

€3.08B

-2.2%

Gross Margin

59.70%

N/A

Market Cap

$73.43BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.18M

N/A

Employees

62,461

N/A

Net Income

€662.51M

-9.9%

EBITDA

€1.49B

-0.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

€3.77B

+133.0%

Total Debt

€12.08B

+28.4%

Accounts Receivable

€4.80B

+7.3%

Inventory

€4.80B

+6.4%

Long Term Debt

€10.84B

+43.9%

Short Term Debt

€1.24B

-28.4%

Return on Assets

4.77%

N/A

Return on Invested Capital

9.30%

N/A

Free Cash Flow

€366.39M

+1045.0%

Operating Cash Flow

€821.11M

+47.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IPSEYIpsen S.A.
$47.68+5.74%
WUXIFWuXi AppTec Co., Ltd.
$20.10-6.73%
HOCPYHOYA Corporation
$153.42+0.58%
SEMHFSiemens Healthineers AG
$43.47+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About MKGAF

What is the current price of Merck KGaA?

Merck KGaA is trading at $168.90 per share.

What is the 52-week range for Merck KGaA?

Over the past 52 weeks, Merck KGaA has traded between $116.68 and $175.56.

How much debt does Merck KGaA have?

As of the most recent reporting period, Merck KGaA reported total debt of €13.87B.

How much cash does Merck KGaA have on hand?

Merck KGaA reported €3.16B in cash and cash equivalents in its most recent financial results.

What is Merck KGaA’s dividend yield?

Merck KGaA currently has a dividend yield of 1.53%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services